ACTRN12610000197033已完成未知
A randomised trial in overweight and obesity men and women, to evaluate the effectiveness of novel strategies to enhance Internet-based weight loss and maintenance of lost weight
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- ARC
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •a history of major medical problems such as heart disease or diabetes; orthopaedic or joint problems that would be a barrier to physical activity such as walking; recently lost 4.5 kg or more in weight; are taking medications that might be affected by weight loss or affect weight loss.
排除标准
- •Have a Body Mass Index (BMI) between 25 and 40; Agree to not participate in other weight loss programs during the study; Pass a health-screening questionnaire and are available for assessment sessions; Have access to a computer with e-mail and Internet facilities
研究者
相似试验
已完成
不适用
Does the rate of weight loss influence the success of long term weight management?Diet and Nutrition - ObesityObesityACTRN12611000190909The University of Melbourne200
已完成
不适用
A randomised trial assessing weight loss and quadriceps strengthening exercises as interventions for reducing knee pain in the community in overweight peopleKnee pain, obesityMusculoskeletal DiseasesKnee painISRCTN93206785Arthritis Research Campaign (ARC) (UK)389
招募中
不适用
A clinical trial evaluating anti-obesity and antilipidemic effects of Schizandra chinensisEndocrine, nutritional and metabolic diseaseKCT0000649Dongguk University Ilsan Oriental Hospital30
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or ObeseHealthy ParticipantsNCT06132841AstraZeneca104
已完成
1 期
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or ObeseHealthy ParticipantsNCT05511025AstraZeneca54